TELOGENOMICS
Precision Medicine

NEWS RELEASE

Telo Genomics Provides Update on Private Placement

Toronto, Ontario, November 6, 2019 – Telo Genomics Corp. (TSX-V: TELO) (the "**Company**" or "**TELO**"). announces that further to its news release dated October 11, 2019, the Company is proceeding with its non-brokered private placement of up to 13,000,000 units at a price of $0.10 per unit for gross proceeds of up to $1,300,000 (the "**Offering**"). In addition, the Company has an over-allotment option to sell up to an additional 5,000,000 units at the offering price.

Each unit will consist of one post-consolidation common share of the Company and one-half of one non-transferable common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional post-consolidation common share at a price of $0.20 per share for a period of 12 months from the date of issuance.

In connection with the Offering, the Company may pay a finder's fee to arm's length parties. The finder's fee will consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and/or finder's warrants equal in number to 7% of the units sold under the Offering. Each finder's warrant will entitle the holder to acquire one post-consolidation common share of the Company at a price of $0.10 per share for a period of 12 months from the date of issuance.

Based on a recently peer-reviewed publication by Dr. Sabine Mai, founder and director of the Company, using TELO's analytical telomere technology, the Company is reviewing a potential opportunity to pursue the assessment of prognostic tests for multiple myeloma as a priority indication. TELO has also identified implementing automation and artificial intelligence to its workflow as a secondary priority initiative. The proceeds from the Offering will be used for general working capital and to pursue these potential opportunities if the Company's review of such opportunities is favourable.

The Company is still proceeding with its previously announced debt settlement to settle up to $1,000,000 of debt with creditors through the issuance of units and shares of the Company.

The Company is proceeding with its previously announced consolidation of its issued and outstanding common shares on the basis of five (5) pre-consolidation common shares for one (1) post-consolidation common share. The Company intends to complete the consolidation prior to the completion of the Offering and debt settlement.

The securities issued pursuant to the Offering and debt settlement will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering, debt settlement and consolidation are subject to t TSX Venture Exchange acceptance.

The securities offered have not been and will not be registered under the United States *Securities Act of 1933*, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.

For further information, please contact:

Hugh Rogers
Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. news wire services or dissemination in the United States.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the consolidation, the Offering, the use of proceeds, the payment of finder's fees and the debt settlement are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.